You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

Clinical Advances in

Improving Diabetes Care with Novel Insulin Therapies

Despite various treatment alternatives and enhanced insulin formulations, type 2 diabetes often remains uncontrolled in many patients for far too long, thus increasing the risk for serious long-term complications. The causes of clinical inertia with respect to insulin initiation and intensification are varied and include concerns such as weight gain, risk of hypoglycemia, and cumbersome or inflexible dosing regimens. Next-generation basal insulin analogues and novel combination regimens with GLP-1 agonists may help physicians to overcome this inertia.

Supported by an independent educational grant from

Novo Nordisk

CME Activities

See All

Polling Question


A 58-year-old man with T2DM is on metformin and a sulphonylurea. His HbA1c is 8.9%, FPG 170 mg/dL (9.4 mmol/L). What is your next therapeutic choice?
Add a third oral drug (eg, DPP-4 inhibitor or SGLT2 inhibitor)
Add a basal insulin
Add a GLP-1 receptor agonist
Add a basal insulin/GLP-1 receptor agonist combination
Other choice

Related Resources

Downloadable Slide Kit

Improving Diabetes Care with Novel Insulin Therapies

A slide kit on the role of insulin in T2D management, insulin intensification options and novel insulin combinations

Download

Clinical Articles

Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;12:1-10.  

Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycaemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015 Jan;38(1):140-9.  

Khunti K, Davies MJ, Kalra S. Self-titration of insulin in the management of people with type 2 diabetes: a practical solution to improve management in primary care. Diabetes Obes Metab. 2013 Aug;15(8):690-700.  

Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014 Nov;2(11):885-93.  

Related Links

See All

Steering Committee

Chantal Mathieu, MD, PhD

Chantal Mathieu, MD, PhD

Steering Committee Chair

Professor of Medicine; Head of Endocrinology, Laboratory of Experimental Medicine Endocrinology (LEGENDO), Katholieke Universiteit Leuven, Leuven, Belgium

Stephen C. Bain, MD, MBBS, FRCP

Stephen C. Bain, MD, MBBS, FRCP

Professor of Medicine (Diabetes), Institute of Life Science, Swansea University College of Medicine, Swansea, United Kingdom

Stephen Colagiuri, MD

Stephen Colagiuri, MD

Professor of Metabolic Health, Boden Institute of Obesity, Nutrition and Exercise, University of Sydney, Sydney, Australia

Andreas Liebl, MD

Andreas Liebl, MD

Medical Director, Center for Diabetes and Metabolism, Fachklinik Bad Heilbrunn, Bad Heilbrunn, Germany

Luc Martinez, MD

Luc Martinez, MD

Former Associate Professor of Family Medicine, University Pierre et Marie Curie; Vice President, French Society of General Medicine, Paris, France

Athena Philis-Tsimikas, MD

Athena Philis-Tsimikas, MD

Corporate Vice President, SCRIPPS HEALTH (Scripps Whittier Diabetes Institute), San Diego, California